Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Chambers Michael Andrew, Director. Director active across 1 company, notably Sarepta Therapeutics, Inc.. Cumulatively, 11 disclosures have been logged. Split: 6 buys · 0 sell. Total volume traded: €11.2m. Activity tracked since 2 June 2022. The latest transaction was filed on 16 August 2024 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Chambers Michael Andrew
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Michael Andrew Chambers is a Board Member at Sarepta Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for rare diseases. As a board member, he participates in overseeing the company's strategies and making key decisions. Michael brings expertise in biopharmacy and product development.